Back to search results

Maintaining Weight Loss After Stopping GLP-1 Medications

This study is looking at ways to help people keep off weight they lost using GLP-1 medications like Ozempic or Wegovy, after they stop taking them. Researchers are testing if different combinations of existing medications—metformin, rapamycin, and low-dose naltrexone—can help prevent weight regain. You might be able to join if you are between 40 and 85 years old, have a BMI of 22 or higher, have been on a GLP-1 medication for at least three months, and have lost at least 15 pounds. The study will measure how well these alternative therapies work over six months to maintain your weight loss. The current status of this study is unclear.

Study design
This is a randomized, controlled study planning to enroll 150 participants. Participants will receive increasing doses of metformin, rapamycin, or low-dose naltrexone, or a placebo (inactive substance) of Vitamin C.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main goals of the study are measured at 6 months after you stop GLP-1 medications.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07092618

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

Recruiting
PHASE2Ages 40–85InterventionalPrevention
AgelessRx
~150 participants
Updated 2025-07-30 on ClinicalTrials.gov
What's tested:MetforminRapamycinNaltrexoneVitamin C

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)
Measured over 6 months
+2 more outcomes measured

Conditions

Longevity
GLP-1
Geroscience
Aging

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Stefanie Morgan, PhD · PRINCIPAL_INVESTIGATOR · AgelessRx

Who to contact

Sajad Zalzala, MD
[email protected]
(313) 355-8657
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Existing AgelessRx patient
Adults (40 - 85 years of age)
Any sex
Any ethnicity
BMI ≥ 22 kg/m\^2
Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation
Have lost at least 15 lbs during their GLP-1 use

Exclusion

Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
History of bariatric surgery
Use of weight-loss medications other than GLP-1s within the past 6 months
Age \<40 years
Contraindications to naltrexone, metformin, or rapamycin
Significant psychiatric illness that may affect participation
Pregnant or breastfeeding individuals

What this trial measures

  • Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)6 months

    Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline. 1. Individuals that maintain the relative weight over the course of six months post-GLP-1 receptor agonist cessation 2. Individuals that have less weight gain over the course of six months post-GLP-1 receptor agonist cessation using the combinatorial therapies than those who do not

  • Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)6 months

    Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.

  • Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)6 months

    Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.